SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-161937"
 

Search: onr:"swepub:oai:DiVA.org:uu-161937" > Phase II Randomized...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Pili, Roberto (author)

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

  • Article/chapterEnglish2011

Publisher, publication year, extent ...

  • 2011
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-161937
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-161937URI
  • https://doi.org/10.1200/JCO.2011.35.6295DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Purpose: The activity of the novel antitumor agent tasquinimod (TASQ) with S100A9 as a molecular target was investigated in men with metastatic castration-resistant prostate cancer (CRPC) and minimal symptoms. Patients and Methods: We conducted a randomized, double-blind, placebo-controlled phase II trial in men assigned (at a ratio of two to one) to either oral once-daily TASQ 0.25 mg/d escalating to 1.0 mg/d over 4 weeks or placebo. The primary end point was the proportion of patients without disease progression at 6 months, defined by Response Evaluation Criteria in Solid Tumors Group, Prostate Cancer Working Group (PCWG2), or pain criteria, excluding prostate-specific antigen. Results: Two hundred one men (134 assigned to TASQ; 67 to placebo) were evaluable, and baseline characteristics were well balanced. Six-month progression-free proportions for TASQ and placebo groups were 69% and 37%, respectively (P < .001), and median progression-free survival (PFS) was 7.6 versus 3.3 months (P = .0042). In PCWG2 CRPC clinical subgroups, PFS in months was as follows: nodal metastases, 6.1 versus 3.1; bone metastases, 8.8 versus 3.4; and visceral metastases, 6.0 versus 3.0 for patients receiving TASQ versus placebo, respectively. Bone alkaline phosphatase levels were stabilized in the TASQ group, whereas the impact on PSA kinetics was less pronounced. Adverse events (AEs) occurring more frequently in the TASQ arm included GI disorders, fatigue, musculoskeletal pains, and elevations of pancreatic and inflammatory biomarkers. Grade 3 to 4 AEs, including asymptomatic elevations of laboratory parameters, were reported in 40% of patients receiving TASQ versus 10% receiving placebo; deep vein thrombosis (4% v 0%) was more common in the TASQ arm. Conclusion: TASQ significantly slowed progression and improved PFS in patients with metastatic CRPC with an acceptable AE profile.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Häggman, MichaelUppsala universitet,Urologkirurgi(Swepub:uu)michhagg (author)
  • Stadler, Walter M. (author)
  • Gingrich, Jeffrey R. (author)
  • Assikis, Vasileios J. (author)
  • Bjork, Anders (author)
  • Nordle, Orjan (author)
  • Forsberg, Goran (author)
  • Carducci, Michael A. (author)
  • Armstrong, Andrew J. (author)
  • Uppsala universitetUrologkirurgi (creator_code:org_t)

Related titles

  • In:Journal of Clinical Oncology29:30, s. 4022-40280732-183X1527-7755

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view